Apricus Biosciences

Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus has initiated a Phase 2b trial for fispemifene, a selective estrogen receptor modulator for the treatment of symptomatic male secondary hypogonadism, and plans to conduct additional studies in other urological conditions. Apricus recently completed enrollment in a Phase 2a trial for RayVa™, its product candidate for the treatment of the circulatory disorder Raynaud’s phenomenon. Apricus’ lead commercial product, Vitaros®, for the treatment of ED, is approved in Europe and Canada and is being commercialized in several countries in Europe. Apricus’ marketing partners for Vitaros include Mylan NV, Takeda Pharmaceuticals International GmbH, Hexal AG (Sandoz), Recordati Ireland Ltd. (Recordati S.p.A.), Bracco S.p.A. and Laboratoires Majorelle. Apricus’ second-generation room temperature Vitaros is under development. Apricus Biosciences is headquartered in San Diego, CA and is publicly traded on the Nasdaq Capital Market under the ticker symbol APRI.
Company Growth (employees)
San Diego, US
Size (employees)
24 (est)
Apricus Biosciences is headquartered in San Diego, US

Apricus Biosciences Office Locations

Apricus Biosciences has an office in San Diego
San Diego, US (HQ)
300 11975 El Camino Real

Apricus Biosciences Metrics

Apricus Biosciences Financial Metrics

Revenue (2016)

$5.8 m

Revenue growth (2015-16), %


Gross profit

$5.3 m

Gross profit margin (2016), %


Net income (2016)

($7.4 m)

Market capitalization (21-Mar-2017)

$16.9 m

Closing share price (21-Mar-2017)


Cash (31-Dec-2016)

$2.1 m
Apricus Biosciences's current market capitalization is $16.9 m.
Apricus Biosciences's revenue was reported to be $5.8 m in 2016
FY, 2013FY, 2014FY, 2015Y, 2016


$2.5 m$9.3 m$4.8 m$5.8 m

Revenue growth, %


Cost of goods sold

$23 k$918 k$922 k$511 k

Gross profit

$2.5 m$8.3 m$3.9 m$5.3 m

Gross profit Margin, %


Operating expense total

$17.2 m$30.9 m$25.3 m$15.3 m


($17.4 m)($22.6 m)($21.4 m)

EBIT margin, %


Interest expense

$727 k$339 k$845 k$1 m

Income tax expense

Net Income

($16.9 m)($21.8 m)($19 m)($7.4 m)
FY, 2013FY, 2014FY, 2015FY, 2016


$21.4 m$11.4 m$3.9 m$2.1 m

Accounts Receivable

$59 k$678 k$519 k$530 k


$336 k$275 k$469 k$764 k

Current Assets

$22.3 m$13.3 m$6.3 m$3.6 m


$955 k$1.4 m$1.3 m$1 m

Total Assets

$23.3 m$14.8 m$7.9 m$4.7 m

Accounts Payable

$926 k$860 k$1.6 m$960 k

Total Debt

$306 k

Current Liabilities

$11.8 m$6.9 m$15.8 m$11.3 m

Additional Paid-in Capital

$279 m$291.7 m$298.9 m$308.8 m

Retained Earnings

($268.1 m)($289.9 m)($308.9 m)($316.3 m)

Debt to Assets Ratio

0 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($16.9 m)($21.8 m)($19 m)($7.4 m)

Depreciation and Amortization

$77 k$170 k$300 k$289 k

Accounts Receivable

$253 k($620 k)$159 k($11 k)


($341 k)$61 k($194 k)($295 k)

Accounts Payable

($920 k)($66 k)$609 k($509 k)

Cash From Operating Activities

$6.3 m($10 m)($7.5 m)($13.1 m)

Purchases of PP&E

($573 k)($580 k)($337 k)

Cash From Investing Activities

$265 k

Interest Paid

$238 k$193 k$538 k$646 k

Income Taxes Paid

$6 k

Apricus Biosciences Market Value History

Apricus Biosciences Online Presence

Apricus Biosciences News

Apricus Biosciences Company Life

You may also be interested in